References
- Addolorato G., Caputo F., Capristo E., Stefanini G. F., Gasbarrini G. Gamma-hydroxybutyric acid: Efficacy, potential abuse, and dependence in the treatment of alcohol addiction. Alcohol 2000; 20: 217–222, [PUBMED], [INFOTRIEVE]
- Bialer P. A. Designer drugs in general hospital. Psychiatr. Clin. North Am. 2002; 25: 231–243, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- Barnas C., Rossmann M., Roessler H., Riemer Y., Fleischhacker W. W. Benzodiazepines and other psychotropic drugs abused by patients in a methadone maintenance program: Familiarity and preference. J. Clin. Psychopharmacol. 1992; 12: 397–402, [PUBMED], [INFOTRIEVE]
- Bond A., Seijas D., Dawling S., Lader M. Systemic absorption and abuse liability of snorted flunitrazepam. Addiction 1994; 89: 821–830, [PUBMED], [INFOTRIEVE]
- Bourke D. L., Malit L. A., Smith T. C. Respiratory interactions of ketamine and morphine. Anesthesiology 1987; 66: 153–156, [PUBMED], [INFOTRIEVE]
- Calhoun S. R., Wesson D. R., Galloway G. P., Smith D. E. Abuse of flunitrazepam (Rohypnol). and other benzodiazepines in Austin and South Texas. J. Psychoactive Drugs 1996; 28: 183–189, [PUBMED], [INFOTRIEVE]
- Centers f or, Disease Control (CDC). Epidemiologic notes and reports of multistate outbreak of poisonings associated with illicit use of gamma hydroxybutyrate. MMWR 1990; 39: 861–863
- Cotman C. W., Monaghan D. T. Chemistry and anatomy of excitatory amino acid systems. Psychopharmacology: The Third Generation of Progress. Raven, New York 1987; pp. 194–210
- Craig K., Gomez H. F., McManus J. L., Bania T. C. Severe gamma-hydroxybutyrate withdrawal: A case report and literature review. J. Emerg. Med. 1999; 18: 65–70, [CROSSREF], [CROSSREF]
- Croft R. J., Mackay A. J., Mills A. T. D., Gruzelier J. G. H. The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology 2001; 153: 373–379, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- Darke S. G., Ross J. E., Hall W. D. Benzodiazepine use among injecting heroin users. Med. J. Aust. 1995; 162: 645–647, [PUBMED], [INFOTRIEVE]
- http://www.dea.gov/concern/ghb_factsheet.html, Drug Enforcement Administration (DEA) (accessed January 2004a)
- http://www.dea.gov/pubs/intel/01026/index.html, Drug Enforcement Administration (DEA) (accessed January 2004b)
- Dyer J. E. Gamma-hydroxybutyrate: A health-food product producing coma and seizurelike activity. Am. J. Emerg. Med. 1991; 9: 321–324, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- Dyer J. E., Roth B., Hyma B. A. Gamma-hydroxybutyrate withdrawal syndrome. Ann. Emerg. Med. 2001; 37: 147–153, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- Farre M., Teran M. T., Cami J. A comparison of the acute behavioral effects of flunitrazepam and triazolam in healthy volunteers. Psychopharmacology 1996; 125: 1–12, [PUBMED], [INFOTRIEVE]
- Farre M., Teran M. T., Roset P. N., Mas M., Torrens M., Cami J. Abuse liability of flunitrazepam among methadone-maintained patients. Psychopharmacology 1998; 140: 486–495, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- Freese T. E., Miotto K., Reback C. J. The effects and consequences of selected club drugs. J. Subst. Abuse Treat. 2002; 23: 151–156, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- Friedman J., Westlake R., Furman M. ‘Grievous bodily harm:’ Gamma hydroxybutyrate abuse leading to a Wernicke-Korsakoff syndrome. Neurology 1996; 46: 469–471, [PUBMED], [INFOTRIEVE]
- Gallimberti L., Cibin M., Pagnin P., Sabbion R., Panni P. P., Pirastu R., Ferrara S. D., Gessa D. L. Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome. Neuropsychopharmacology 1993; 9: 77–81, [PUBMED], [INFOTRIEVE]
- Gallimberti L., Gentile N., Cibin M., Fadda F., Canton G., Ferri M., Ferrara S. D., Gessa G. L. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet 1989; 2: 787–789, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- Galloway G. P., Frederick S. L., Staggers F. E., Jr., Gonzales M., Stalcup S. A., Smith D. E. Gamma-hydroxybutyrate: An emerging drug of abuse that causes physical dependence. Addiction 1997; 92: 89–96, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- Galloway G. P., Frederick-Osborne S. L., Seymour R., Contini S. E., Smith D. E. Abuse and therapeutic potential of gamma-hydroxybutyric acid. Alcohol 2000; 20: 263–269, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- George K. A., Dundee J. W. Relative amnesic actions of diazepam, flunitrazepam and lorazepam in man. Br. J. Clin. Pharmacol. 1977; 4: 45–50, [PUBMED], [INFOTRIEVE]
- Greer G. R., Tolbert R. A method of conducting therapeutic sessions with MDMA. J. Psychoactive Drugs 1998; 30: 371–379, [PUBMED], [INFOTRIEVE]
- Harris J. A., Biersner R. J., Edwards D., Bailey L. W. Attention, learning, and personality during ketamine emergence: A pilot study. Anesth. Analg. 1975; 54: 169–172, [PUBMED], [INFOTRIEVE]
- Ingels M., Rangan C., Bellezzo J., Clark R. F. Coma and respiratory depression following the ingestion of GHB and its precursors: Three cases. J. Emerg. Med. 2000; 19: 47–50, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- Klitzman R. L., Pope H. G., Jr., Hudson J. L. MDMA (“Ecstasy”) abuse and high-risk sexual behaviors among 169 gay and bisexual men. Am. J. Psychiatry 2000; 157: 1162–1164, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- Koesters S. C., Rogers P. D., Rajasingham C. R. MDMA (‘ecstasy’) and other ‘club drugs’: The new epidemic. Pediatr. Clin. North Am. 2002; 49: 415–433, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- Krystal J. H., Karper L. P., Seibyl J. P., Freeman G. K., Delaney R., Bremner J. D., Heninger G. R., Bowers M. B., Jr., Charney D. S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994; 51: 199–214, [PUBMED], [INFOTRIEVE]
- Laborit H. Sodium 4-hydroxybutyrate. Int. J. Neuropharmacol. 1964; 43: 433–452, [CROSSREF], [CROSSREF]
- Lammers G. J., Arends J., Declerck A. C., Ferrari M. D., Schouwink G., Troost J. Gammahydroxybutyrate and narcolepsy: A double-blind, placebo-controlled study. Sleep 1993; 16: 216–220, [PUBMED], [INFOTRIEVE]
- Li J., Stokes S. A., Woeckener A. A tale of novel intoxication: Seven cases of gamma-hydroxybutyric acid overdose. Ann. of Emerg. Med. 1998; 31: 723–728
- Liechti M. E., Bauman C., Gamma A., Vollenweider F. X. Acute psychological effects of 3,4–methylenedioxy-methamphetamine (MDMA, “ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 2000; 22: 513–521, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- Mansikka M., Kangas L., Kanto J. A comparative study on the clinical effects of flunitrazepam and lorazepam. Int. J. Clin. Pharmacol. Ther. Toxicol. 1980; 18: 320–321, [PUBMED], [INFOTRIEVE]
- Mattila M. A. K., Larni H. M. Flunitrazepam: A review of its pharmacological properties and therapeutic use. Drugs 1980; 20: 353–374, [PUBMED], [INFOTRIEVE]
- McCann U. D., Szabo Z., Scheffel U., Dannals R. F., Ricaurte G. A. Positron emission tomographic evidence of toxic effect of MDMA (“ecstasy”) on brain serotonin neurons in human beings. Lancet 1998; 352: 1433–1437, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- McDaniel C. H., Miotto K. A. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: Five case studies. J. Psychoactive Drugs 2001; 33: 143–149, [PUBMED], [INFOTRIEVE]
- Mintzer M. Z., Griffiths R. R. Flunitrazepam and triazolam: A comparison of behavioral effects and abuse liability. Drug Alcohol Depend. 1998; 53: 49–66, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- http://www.maps.org/research/mdmaplan.html, Multidisciplinary Association for Psychedelic Studies (MAPS). (accessed May 2004)
- http://www.drugabuse.gov/clubalert/clubdrugalert.html, (National Institute on Drug Abuse (NIDA). NIDA Community Drug Alert Bulletin-Club Drugs. (accessed Dec. 26, 2003)
- O'Connor B. Hazards associated with the recreational drug “ecstasy”. Br. J. Hosp. Med. 1994; 52: 507–514, [PUBMED], [INFOTRIEVE]
- http://www.whitehousedrugpolicy.gov/drugfact/club/club_b.html#go3, Office of National Drug Control Policy. (accessed January 2004a)
- http://www.whitehousedrugpolicy.gov/publications/factsht/rohypnol, Office of National Drug Control Policy. (accessed October 2004b)
- Orphan Medical, Inc., http://www.xyrem.info/dosadmin.htm (accessed October 2004)
- Perel A., Davidson J. T. Recurrent hallucinations following ketamine. Anaesthesia 1976; 31: 1081–1083, [PUBMED], [INFOTRIEVE]
- Ricaurte G. A., McCann U. D., Szabo Z., Scheffel U. Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Toxicology Letters 2000; 112–113: 143–146, [CROSSREF], [CROSSREF]
- Rome E. S. It's a rave new world: Rave culture and illicit drug use in the young. Cleve. Clin. J. Med. 2001; 68: 541–550, [PUBMED], [INFOTRIEVE]
- San L., Tato J., Torrens M., Castillo C., Farre M., Cami J. Flunitrazepam consumption among heroin addicts admitted for in-patient detoxification. Drug Alcohol Depend. 1993; 32: 281–286, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- Scharf M. B., Hauck M., Stover R., McDannold M., Berkowitz D. Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Preliminary report. J. Rheumatol. 1998; 25: 1986–1990, [PUBMED], [INFOTRIEVE]
- Schwartz R. H., Milteer R., LeBeau M. A. Drug-facilitated sexual assault (‘date rape’). South. Med. J. 2000; 93: 558–561, [PUBMED], [INFOTRIEVE]
- Schwartz R. H., Weaver A. B. Rohypnol, the date rape drug. Clin. Pediatr. 1998; 37: 321–322
- Smith K. M., Larive L. L., Romanelli F. Club drugs: Methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and γ -hydroxybutyrate. Am. J. Health-Syst. Pharm. 2002; 59: 1067–1076, [PUBMED], [INFOTRIEVE]
- Sporer K. A., Chin R. L., Dyer J. E., Lamb R. Gamma-hydroxybutyrate serum levels and clinical syndrome after severe overdose. Ann. Emerg. Med. 2003; 42: 3–8, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- Steele M. T., Watson W. A. Acute poisoning from gamma hydroxybutyrate (GHB). Mo. Med. 1995; 92: 354–357, [PUBMED], [INFOTRIEVE]
- http://www.erowid.org/chemicals/mdma/mdma_law2.shtml, U.S. Department of Justice, Drug Enforcement Administration (1986). In the matter of MDMA scheduling (Docket No. 84-48): Opinion and recommended ruling, findings of fact, conclusions of law and decision of administrative law judge on issues two through seven [On-line].Available:
- U.S. Department of Justice, Drug Enforcement Administration. Schedules of Controlled Substances; Deletion of 3,4 Methylenedioxymethamphetamine (MDMA) from Schedule I of the Controlled Substances Act. Federal Register 1988a; 53(17)2225
- U.S. Department of Justice, Drug Enforcement Administration. Schedules of Controlled Substances; Scheduling of 3, 4 Methylenedioxymethamphetamine (MDMA) Into Schedule I of the Controlled Substances Act; Remand. Federal Register 1988b; 53(34)5156–5158
- http://www.usdoj.gov/ndic/pubs1/1621/1621t.htm, U.S. Department of Justice. (2002) Information Bulletin [On-line]. Available:
- http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01157.html, U.S. Food and Drug Administration (FDA) (2002). FDA approves Xyrem for cataplexy attacks in patients with narcolepsy [On-line]. Available:
- Vollenweider F. X., Gamma A., Liecthi M., Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naïve healthy volunteers. Neuropsychopharmacology 1998; 19: 241–251, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
- Weiner A. L., Vieira L., McKay C. A., Jr., Bayer M. J. Ketamine abusers presenting to the emergency department: A case series. J. Emerg. Med. 2000; 18: 447–451, [PUBMED], [INFOTRIEVE]